Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik(BioNTech (Germany)), Ignacio Melero(Universidad de Navarra)
Cited by 0
Related Papers
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
|Immunity|2020|749
Immunostimulatory monoclonal antibodies for cancer therapy
|Nature reviews. Cancer|2007|628
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
|Nature Reviews Clinical Oncology|2021|469
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
|Clinical Cancer Research|2020|109